$5M Grant Supports Phase 1 Trial of AAV2-BDNF, Potential Gene Therapy

$5M Grant Supports Phase 1 Trial of AAV2-BDNF, Potential Gene Therapy

296583

$5M Grant Supports Phase 1 Trial of AAV2-BDNF, Potential Gene Therapy

The National Institute on Aging (NIA) has awarded a five-year grant worth up to $5 million to support a clinical trial that will test AAV2-BDNF, an investigational gene therapy, in people with Alzheimer’s disease or mild cognitive impairment, which often precedes dementia. The therapy aims to deliver the gene BDNF to cells within specific regions of the brain by using an engineered adeno-associated virus (AAV2). This would prompt the cells to “read” the gene and produce the…

You must be logged in to read/download the full post.